HER-2-positive breast cancer
Impressive Objective Response to Nab Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER 2 Positive Breast Cancer Patient
8
An In-Vivo Investigation of the Cardio-Protective Potential of Aspirin, β-oestradiol and Calcipotriol for Trastuzumab Treatment of Her-2 Positive Breast Cancer
17
Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway
15
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
9
Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
11
Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis
12
<p>A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab</p>
9
HER 2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy
9
Evidence Based Medicine, in Precision Oncology
17
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
10
Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
16
Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels
12
Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
11
2. STUDY OF METASTATIC CANCER OF BREAST WITH SPECIAL REFERENCE TO BREAST CANCER SUBTYPES
9
Tumor escape and progression of HER 2/neu negative breast cancer under immune pressure
5
A correlation study of the expression of HA-CD44st and HER-2 in breast cancer
12
The Effect of Neoadjuvant Chemotherapy on ER, PR and HER 2 Expression in Breast Cancer
13
Association between Overexpression of Her 2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco
6
Quantification of HER family receptors in breast cancer
12
Negative genic switch of HER 2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2 positive breast cancer
5